Myopia

CooperVision to Share New Analysis of MiSight® 1 Day Treatment Effects During International Myopia Conference Event

Retrieved on: 
Thursday, September 1, 2022
Workforce, NYSE, Research, NIH Intramural Research Program, Awareness, Doctor of Philosophy, Disease, The Cooper Companies, Parent, ECP, Presbyopia, Learning, Science, Fertility, Dioptre, Myopia, Conference, Cooper, CEST, CooperVision, Clinical trial, Lens (anatomy), Woman, Bachelor of Science, Benelux, Astigmatism, Health, Genomics, Pharmaceutical industry, Telescopic sight, Honours degree, IMC

ROTTERDAM, Netherlands, Sept. 1, 2022 /PRNewswire/ -- CooperVision's global leadership in myopia control and management will be spotlighted next week at the 18th annual International Myopia Conference, taking place in Rotterdam, the Netherlands. The meeting is expected to attract a record number of attendees, reflecting escalating interest in understanding and addressing the disease and its bearing on children's short- and long-term vision and ocular health.

Key Points: 
  • The international seven-year MiSight1 day clinical trial has become the gold standard for evaluating myopia control effectiveness because of its robust design, multi-country enrollment, and extent of professionally published and peer-reviewed data.
  • The findings will be presented by Paul Chamberlain, BSc (Hons), CooperVision Senior Director of Research Programs, and Arthur Bradley, PhD, CooperVision Research Fellow, on Monday, September 5, at 12:30 pm CEST.
  • "No one is doing more than CooperVision to advance the science and practice of myopia control and management.
  • Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries.

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

Retrieved on: 
Tuesday, August 30, 2022
COVID-19, CEO, Technology, Ophthalmology, NASDAQ, Mydriasis, Stinger, Glaucoma, Physician, Presbyopia, U.S. Securities and Exchange Commission, Microcline, GLOBE, Therapy, Face, Eye, Forward-looking statement, Marketing, Patient, MAP, Pharmaceutical industry, Myopia

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, brings human-centric design to ophthalmology with its novel Optejet dispenser.

Key Points: 
  • NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, brings human-centric design to ophthalmology with its novel Optejet dispenser.
  • Eyenovia's easy-to-use, novel Optejet dispenser administers precisely 8L of medication to the eye, effectively treating the patient's condition while creating a more gentle dosing experience.
  • "The unique delivery mechanism oftheOptejet will fundamentally change how we think about eye medication," said Michael Rowe, CEO of Eyenovia.
  • Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements.

Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation

Retrieved on: 
Monday, August 29, 2022
Keratoconus, Burns, NYSE, GKOS, Clinical trial, Lawyer, Intellectual property, Employment, Myopia, Pharmaceutical industry

BOSTON, Aug. 29, 2022 /PRNewswire/ -- Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, in a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS).

Key Points: 
  • BOSTON, Aug. 29, 2022 /PRNewswire/ -- Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, in a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS).
  • On August 24, iVeena announced that it has licensed its lead asset, IVMED-80, an Orphan Drug Designated eye drop for keratoconus to Glaukos.
  • The agreement grants Glaukos an exclusive global license to develop and commercialize IVMED-80.As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with the development and regulatory activities on IVMED-80.
  • The Burns & Levinson intellectual property team was led by Partner Bruce Jobse , who provided advice and counsel during the drafting and negotiations of the license agreement with Glaukos.

SunLike Lighting, With Proven Effectiveness of Myopia Improvement, to Light up a Major English-Speaking Kindergarten in Korea

Retrieved on: 
Monday, September 19, 2022
Hardware, Optical, Consumer Electronics, Consumer, Technology, Preschool, Construction & Property, Education, Children, Building Systems, Other Technology, Health, Interior Design, University, Myopia, University of Basel, Human, SERI, Time, Disease, Prism, Â, Parent, Multimedia, Student, Apple tree, School, Harvard University, Seoul Semiconductor, Main sequence, YBM, Language, Lighting, Eye, Seoul National University, Health, LED, Television, Hardware, Optical, Consumer Electronics, Consumer, Technology, Preschool, Construction & Property, Education, Children, Building Systems, Other Technology, Health, Interior Design

It is well-known among discerning Korean parents for its strict standards for teachers and step-by-step curriculum.

Key Points: 
  • It is well-known among discerning Korean parents for its strict standards for teachers and step-by-step curriculum.
  • The kindergarten always makes sure to provide the best educational environment, and this time they have installed SunLike lighting, which reproduces natural light, in the entire language academy to help correct their students myopia.
  • SunLike is based on an innovative lighting technology that re-creates natural light spectrum.
  • In January 2022, the company proved that the natural spectrum lighting has corrective effects for myopia jointly with the Singapore Eye Research Institute (SERI).

Video Games Market to Grow Three-Fold, Surpassing US$ 510 Billion by 2031; Google and Meta to be the Trendsetters

Retrieved on: 
Thursday, August 25, 2022
Augmented reality, Technology, Smartphone, VR, Meta, Microsoft, Traction, Data, Unity Technologies, AR, Parent, Apple, NEW, Oculus (brand), Myopia, CAGR, Internet, Activision Blizzard, Video, Virtual reality, Video game, Video game console, Google

NEW YORK, Aug. 25, 2022 /PRNewswire/ -- The global video games market is likely to grow at 13% CAGR between 2021 and 2031. Global video games sales are expected to reach almost US$ 510 billion by 2031, with developing countries accounting for sizeable demand during the forecast period (2021-2031).

Key Points: 
  • The video games market analysis offered by Fact.MR scrutinizes key growth factors that are impacting sales in the market.
  • NEW YORK, Aug. 25, 2022 /PRNewswire/ --The global video games market is likely to grow at 13% CAGR between 2021 and 2031.
  • Global video games sales are expected to reach almost US$ 510 billion by 2031 , with developing countries accounting for sizeable demand during the forecast period (2021-2031).
  • The video game market continues to witness steady growth, prompting tech giants such as Google, Microsoft Facebook, and Apple to enter this lucrative space.

Video Games Market to Grow Three-Fold, Surpassing US$ 510 Billion by 2031; Google and Meta to be the Trendsetters

Retrieved on: 
Thursday, August 25, 2022
Augmented reality, Technology, Smartphone, VR, Meta, Microsoft, Traction, Data, Unity Technologies, AR, Parent, Apple, NEW, Oculus (brand), Myopia, CAGR, Internet, Activision Blizzard, Video, Virtual reality, Video game, Video game console, Google

NEW YORK, Aug. 25, 2022 /PRNewswire/ -- The global video games market is likely to grow at 13% CAGR between 2021 and 2031. Global video games sales are expected to reach almost US$ 510 billion by 2031, with developing countries accounting for sizeable demand during the forecast period (2021-2031).

Key Points: 
  • The video games market analysis offered by Fact.MR scrutinizes key growth factors that are impacting sales in the market.
  • NEW YORK, Aug. 25, 2022 /PRNewswire/ --The global video games market is likely to grow at 13% CAGR between 2021 and 2031.
  • Global video games sales are expected to reach almost US$ 510 billion by 2031 , with developing countries accounting for sizeable demand during the forecast period (2021-2031).
  • The video game market continues to witness steady growth, prompting tech giants such as Google, Microsoft Facebook, and Apple to enter this lucrative space.

Glaukos Licenses Iveena’s Investigational Keratoconus Therapy

Retrieved on: 
Wednesday, August 24, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Technology, NYSE, Retina, Cornea, Glaucoma, GKOS, ODD, LOX, Myopia, MIGS, Keratoconus, Glaucoma surgery, Clinical trial, Trial of the century, Patient, Pharmaceutical industry

iVeena Delivery Systems Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus.

Key Points: 
  • iVeena Delivery Systems Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus.
  • Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States.
  • Glaukos is a strong partner to complete development of this product where, if approved, patients will have an additional keratoconus treatment option.
  • iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus.

Back-to-school prep: The Canadian Ophthalmological Society urges parents to monitor children's vision to start the school year off right

Retrieved on: 
Tuesday, August 23, 2022
Royal college, RCPSC, American Ophthalmological Society, Ophthalmology, Leger, Ageing, Physician, CPD, Government, Professional development, Achievement Medal, COS, Eye Health UK, Royal College of Physicians and Surgeons of Canada, Parent, CMA, Sport, Learning, Hobby, Probability, Surgeon, Health policy, Myopia, Continuing medical education, Screen time, Risk, Eye, COVID, Canadian Medical Association, Child, Toy

"The start of the school year is always a good time to remember to monitor your child's eyes and determine if they have had any changes to their vision," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.

Key Points: 
  • "The start of the school year is always a good time to remember to monitor your child's eyes and determine if they have had any changes to their vision," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.
  • "A comprehensive evaluation early in the school year is important to detect changes and rectify them before they can have an impact on learning."
  • The survey revealed that 83 per cent of respondents believe that prolonged screen time is harmful to their child(ren)'s eye health.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.

Eyewear Market to Propel at a Robust CAGR of 6% From 2022-2032 Due to Increasing Eye Health Awareness Around the Globe - Future Market Insights, Inc.

Retrieved on: 
Thursday, August 11, 2022
Online, People, Lens (anatomy), Astigmatism, Attitude, Contact lens, Industry, Sport, Lens, Population, Visual impairment, Bandini s.p. 1000, Growth, Millennials, Carl Zeiss AG, Far-sightedness, Snow, Sale, Eye, Myopia, Marketing, Instagram, Eyewear, Social media, Twitter, Urbanization, Ageing, Glasses, Awareness, CAGR, Adoption, Lists of countries and territories, CooperVision, Skiing, Developing country, Advertising, Internet, Health, Organization, Personal protective equipment, Fashion accessory, Facebook, Adidas

NEWARK, Del., Aug. 11, 2022 /PRNewswire/ -- The global eyewear market is anticipated to create an absolute dollar opportunity during the forecast period the demand for eyewear is expected to increase at a CAGR of 6%, from US$ 114.95 billion in 2021 to US$ 205.86 Mn by 2032.

Key Points: 
  • Attributing factors like increased disposable income and higher standards of living have pushed the acceptance of high-end, branded eyewear resulting in high demand for eyewear.
  • The customer base for the eyewear market is increasing due to the proactive attitude of potential customers which is creating chances for the eyewear market and retailers to grow at a fast pace.
  • People are increasingly becoming more aware of their eye health and have realized the importance of regular eye checkups/ examinations.
  • Established manufacturers and major key players in the eyewear market are continuously investing in R&D and increasing their eyewear market share.

Eyewear Market to Propel at a Robust CAGR of 6% From 2022-2032 Due to Increasing Eye Health Awareness Around the Globe - Future Market Insights, Inc.

Retrieved on: 
Thursday, August 11, 2022
Online, People, Lens (anatomy), Astigmatism, Attitude, Contact lens, Industry, Sport, Lens, Population, Visual impairment, Bandini s.p. 1000, Growth, Millennials, Carl Zeiss AG, Far-sightedness, Snow, Sale, Eye, Myopia, Marketing, Instagram, Eyewear, Social media, Twitter, Urbanization, Ageing, Glasses, Awareness, CAGR, Adoption, Lists of countries and territories, CooperVision, Skiing, Developing country, Advertising, Internet, Health, Organization, Personal protective equipment, Fashion accessory, Facebook, Adidas

NEWARK, Del., Aug. 11, 2022 /PRNewswire/ -- The global eyewear market is anticipated to create an absolute dollar opportunity during the forecast period the demand for eyewear is expected to increase at a CAGR of 6%, from US$ 114.95 billion in 2021 to US$ 205.86 Mn by 2032.

Key Points: 
  • Attributing factors like increased disposable income and higher standards of living have pushed the acceptance of high-end, branded eyewear resulting in high demand for eyewear.
  • The customer base for the eyewear market is increasing due to the proactive attitude of potential customers which is creating chances for the eyewear market and retailers to grow at a fast pace.
  • People are increasingly becoming more aware of their eye health and have realized the importance of regular eye checkups/ examinations.
  • Established manufacturers and major key players in the eyewear market are continuously investing in R&D and increasing their eyewear market share.